GR 3027

Drug Profile

GR 3027

Alternative Names: GR3027

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Umecrine Cognition
  • Class Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatic encephalopathy

Most Recent Events

  • 19 Apr 2017 Interim pharmacokinetics and adverse events data from a phase-I trial in Hepatic encephalopathy presented at the International Liver Congress (ILC-2017)
  • 17 Mar 2017 Phase-I/II clinical trials in Hepatic encephalopathy in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top